Cilo Cybin

What Cilo Cybin does

Cilo Cybin is a South African pharmaceutical biotechnology company that operates a vertically integrated platform for regulated cannabinoid production, spanning indoor GACP-compliant cultivation, GMP manufacturing, extraction, refinement, formulation, packaging, and export-ready documentation. The company was founded in 2018, obtained South Africa's first GACP medical cannabis cultivation licence in 2020, and became the country's first fully vertically integrated cannabis company with both GACP and GMP licences in 2021. Its core technical capability sits in a GMP manufacturing platform built around cold ethanol extraction, winterisation, thin-film solvent recovery, decarboxylation, double distillation, and liquid-liquid separation chromatography capable of producing 98%+ refined THC, with distillate throughput of up to 20 litres per hour and indoor cultivation yield of 45-55 kg of dried trimmed flower per 6-week harvest cycle.

The company's product portfolio is organised into three API families — THC (crude 70%+, distillate 88-92%, refined 98%+), CBD (isolate, crystal-resistant distillate, crude 70%+, distillate 85%, CBD-V isolate, Japan-compliant THC-free isolate), and minor cannabinoids (CBN, CBG, CBC, THCV, CBT) — feeding into a finished-format contract manufacturing offering that includes oils and tinctures, vape formats, topicals, capsules, edibles, and secondary packaging. Cilo Cybin operates a purely B2B enterprise go-to-market, targeting licensed international cannabis companies, pharmaceutical partners, medical cannabis brands, and licensed cultivators/distributors requiring GMP-compliant supply for regulated destination markets. Pricing and revenue are not publicly disclosed; buyer enquiries are reviewed through a governed intake workflow before supply discussions, with contract manufacturing terms negotiated on the basis of format, cannabinoid profile, target market, and expected volumes.

The group operates through a listed holding company, Cilo Cybin Holdings Limited (JSE: CCC, transitioned from AltX to the Main Board in 2025 following its 2024 listing), and its core operating subsidiary Cilo Cybin Pharmaceutical (Pty) Ltd, which holds the GACP and GMP licences. The company holds B-BBEE Level 4 contributor status, is headquartered in Centurion, South Africa, and reports 11-50 employees. Revenue, customer counts, and contract values are not publicly disclosed.

Name

Cilo Cybin

Legal name

Cilo Cybin Holdings Limited

Website

https://cilocybin.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Cilo Cybin is a South African pharmaceutical biotech operating a vertically integrated GACP-to-GMP cannabinoid platform. It produces THC, CBD, and minor-cannabinoid APIs and contract-manufactures finished formats for licensed international pharmaceutical and cannabis partners, and is listed on the JSE Main Board (CCC).

Ownership category

akta.pro rank

Product category

Cannabis Pharmaceutical Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cannabis Accessories & Ancillary Products Wholesale (Vapes, Packaging, Hardware) (CRAOAIAH)

akta.pro secondary industry

E-liquids & Nicotine Salts Manufacturing & Brands (CRADAJAG)

Keywords

• Pharmaceutical contract manufacturing
• GMP cannabinoid manufacturing
• Medical cannabis cultivation
• Cannabinoid API production
• Active pharmaceutical ingredients

Headquarters

HQ city

Centurion

HQ country

South Africa

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: GMP contract manufacturing services for licensed partners producing finished cannabinoid products including tinctures, capsules, topicals, vape formats, and secondary packaging under controlled manufacturing workflows.
2. Cannabinoid API Sales: Sale of active pharmaceutical ingredients including THC (crude, distillate, refined), CBD (isolate, CRD, crude, distillate), and minor cannabinoids (CBN, CBG, CBC, THCV, CBT, CBD-V) to licensed pharmaceutical and product-development partners.
3. Finished Product Manufacturing: Manufacturing and supply of finished-format cannabinoid products including oils, tinctures, capsules, edibles, topicals, and vape products for licensed destination markets.
4. Secondary Packaging Services: GMP-ready cannabis flower packaging and secondary packaging services including labelling, batch coding, and release-support documentation for medical cannabis products.
5. Export Supply Programs: Storage, documentation, and export-market support for licensed international cannabinoid product supply through regulated supply pathways.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Cilo Cybin is a South African pharmaceutical biotechnology company that produces and cultivates medical cannabis. It operates a vertically integrated platform spanning GACP-compliant indoor cultivation through GMP-aligned extraction, distillation, isolation, formulation, and packaging. The company manufactures and supplies cannabinoid active pharmaceutical ingredients (THC, CBD, and minor cannabinoid APIs) and offers contract manufacturing of finished-format products including oils, tinctures, capsules, topicals, vape formats, and edibles for licensed international pharmaceutical companies, cannabis brands, and regulated market operators.

Product overview

Cilo Cybin is a South African pharmaceutical biotechnology company offering a vertically integrated cannabinoid platform. The portfolio comprises three main API families: THC products (THC Crude 70%+, THC Distillate 88-92%, Refined THC 98%+), CBD products (CBD Isolate, CBD CRD, CBD Crude 70%+, CBD Distillate 85%, CBD-V Isolate, and Japan-Compliant THC-Free CBD Isolate), and Minor Cannabinoid APIs (CBN Isolate, CBG Isolate, CBG CRD, CBC Isolate, THCV Isolate, CBT Distillate). These APIs feed into finished product contract manufacturing services including Oils & Tinctures, Vape Formats, Topicals, Capsules, Edibles, and Secondary Packaging. The platform is supported by GACP-compliant cultivation (45-55 kg per 6-week cycle) and GMP manufacturing capabilities (up to 20 litres distillate throughput per hour). The company is listed on the JSE (CCC) and operates under SAHPRA-aligned GMP standards.

Differentiator

Problem solved

Functional benefit

Products and services

• THC Crude 70%+

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Aurora Cannabis: Canadian GMP-certified cannabis producer with international medical cannabis operations and EU-GMP facilities supplying pharmaceutical-grade cannabinoid APIs and finished products. Comparable as a multi-market GMP cannabinoid manufacturer.
• Canopy Growth Corporation: Canadian global cannabis leader with extensive GMP-certified cultivation and manufacturing infrastructure producing cannabinoid APIs and pharmaceutical-grade formulations. Comparable as a vertically-integrated cannabis pharmaceutical platform, though far larger in scale.
• OrganiGram Holdings: Canadian licensed cannabis producer with GMP manufacturing of cannabinoid extracts, distillates, and finished products including vapes, capsules, and edibles. Comparable finished-format GMP manufacturing across multiple dosage forms.
• Tilray Brands: Large global cannabis company with GMP manufacturing operations across multiple countries producing cannabinoid APIs and finished products for medical and consumer markets. Comparable as a GMP cannabis manufacturer with international API/finished product supply, though at much larger scale.

Emerging players

• STENOCARE: Danish medical cannabis company producing cannabinoid oils and formulations under EU-GMP for the European medical market. Comparable as a smaller pharmaceutical-format cannabis producer serving regulated international markets.
• Khiron Life Sciences: Latin America-based medical cannabis company with vertically integrated cultivation, extraction, and GMP manufacturing supplying international markets. Comparable as a smaller, internationally-focused GMP cannabinoid manufacturer targeting regulated export markets.

Direct peers

• BOL Pharma: Israeli pharmaceutical-grade cannabis cultivator and manufacturer with IMC-GMP certification producing APIs and finished dosage forms for domestic and international medical markets. Comparable vertically-integrated, pharma-grade cannabis manufacturer with international export focus.
• Clever Leaves: Colombia-based GMP-certified cannabis cultivator and manufacturer producing cannabinoid APIs and finished products for international pharmaceutical and wellness markets. Comparable as a non-domestic (to North America/Europe) GMP cannabis manufacturer serving regulated export channels.
• MediPharm Labs: Canadian GMP-certified cannabis contract manufacturer focused on API supply and white-label finished formats for international partners. Directly comparable business model of GMP contract manufacturing, API sales, and finished-format supply to licensed buyers.

Regional players

• Vitura Health (formerly Cronos Australia): Australian-listed cannabis company focused on medicinal cannabis product supply and distribution in the Australian and Asia-Pacific region. Comparable as a listed medical cannabis platform with GMP-aligned manufacturing and international supply aspirations in the Asia-Pacific region where Cilo Cybin also targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/cilocybin
• LinkedInlinkedin.com/company/cilo-cybin

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cilo Cybin